Overview
PT-141 (bremelanotide), marketed as Vyleesi, is a synthetic cyclic heptapeptide melanocortin receptor agonist that received FDA approval in June 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It represents the first and only FDA-approved on-demand treatment for HSDD, a condition affecting approximately 10% of premenopausal women characterized by persistent lack of sexual desire causing personal distress.
Unlike phosphodiesterase-5 inhibitors (sildenafil, tadalafil) that act peripherally on blood flow, PT-141 works through the central nervous system by activating melanocortin-4 receptors (MC4R) in the hypothalamus, modulating the neural pathways that regulate sexual desire and arousal. This central mechanism makes PT-141 fundamentally different from other sexual dysfunction treatments and represents a new pharmacological approach to desire disorders.
PT-141 was derived from Melanotan II, a broader melanocortin agonist originally studied for tanning effects, after researchers noted significant sexual arousal effects in clinical participants. PALATIN Technologies subsequently developed PT-141 as a more selective MC4R agonist optimized for sexual desire enhancement with reduced melanogenic and other off-target effects.
This guide reviews PT-141's unique mechanism of action, clinical trial data supporting its FDA approval, practical dosing information, safety profile, and considerations for both its approved indication and off-label research interest.
Quick facts
- Mechanism
- MC4R agonist activating central sexual desire pathways
- Primary use
- Sexual Desire Enhancement (HSDD)
- Evidence
- strong
- FDA
- Approved
- Route
- Subcutaneous injection (autoinjector)
- Typical results
- Increased sexual desire within 45 minutes; FDA-approved for on-demand use
Chemical information
PT-141 (C₅₀H₆₈N₁₄O₁₀) is a hormonal compound with a molecular weight of 1025.18 g/mol. Its structural characteristics underpin its biological activity in hormonal signaling and endocrine function.
How PT-141 works
PT-141 activates melanocortin-4 receptors (MC4R) in the medial preoptic area and paraventricular nucleus of the hypothalamus, brain regions critical for the integration of sexual motivation, arousal, and reward. MC4R activation in these regions triggers downstream dopaminergic and oxytocinergic signaling that enhances sexual desire and subjective arousal independent of peripheral vasodilation.
The melanocortin system's role in sexual function was discovered serendipitously during tanning peptide research when subjects receiving Melanotan II reported spontaneous erections and increased sexual desire. Subsequent investigation revealed that MC4R activation in the hypothalamus stimulates the release of oxytocin from the paraventricular nucleus, which activates descending neural pathways to the spinal cord that control genital arousal responses.
PT-141's selectivity for MC4R over other melanocortin receptors (MC1R-MC5R) was optimized to enhance sexual effects while minimizing tanning (MC1R), appetite suppression (MC4R at different sites), and adrenal effects (MC2R). However, some MC1R activation persists, which can cause transient skin flushing and nausea in some patients.
Importantly, PT-141 addresses sexual desire (libido) rather than physical arousal capacity. In clinical trials, women treated with PT-141 reported increased desire to initiate sexual activity, more satisfying sexual encounters, and reduced distress about their low sexual desire—outcomes that reflect central nervous system effects rather than peripheral physiological changes.
- MC4R activation: Stimulates melanocortin-4 receptors in hypothalamic sexual regulation centers
- Dopamine modulation: Enhances dopaminergic signaling in mesolimbic reward pathways
- Oxytocin release: Triggers paraventricular oxytocin release for downstream arousal signaling
- Central vs. peripheral: Acts on brain desire pathways, not peripheral blood flow
- On-demand action: Effects begin within 45 minutes; last up to 24 hours
- Gender-inclusive mechanism: MC4R pathway active in both male and female sexual neurocircuitry
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Bioavailability (SC) | ~100% | Complete absorption from subcutaneous injection |
| Tmax | ~1 hour | Peak plasma levels within 1 hour of injection |
| Half-life | ~2.7 hours | Clinical effects persist 12–24 hours beyond half-life |
| Onset of desire effects | ~45 minutes | On-demand use at least 45 min before anticipated activity |
| Duration of effect | Up to 24 hours | Single dose provides extended window of enhanced desire |
| Metabolism | Hepatic hydrolysis | Standard peptide metabolism; no CYP450 interactions |
Dosing & administration
PT-141 dosing varies by indication and individual factors. Refer to the official prescribing information for approved indications.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Side effects & safety
Safety data for PT-141 is established for approved indications via clinical trials. Long-term effects in humans remain incompletely characterized.
Common
- • Nausea (40% of patients—most common side effect)
- • Flushing (20%)
- • Injection site reactions
- • Headache (11%)
- • Transient blood pressure elevation
- • Hyperpigmentation with repeated use
Serious / potential risks
- • Significant nausea requiring antiemetic in some patients
- • Transient hypertension (not recommended in uncontrolled cardiovascular disease)
- • Focal hyperpigmentation with chronic use
- • Not studied in postmenopausal women or men for approved indication
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| Naltrexone | May reduce PT-141 efficacy through opioid pathway interaction | Combination may diminish sexual desire effects |
| Antihypertensives | PT-141 can transiently raise blood pressure | Monitor blood pressure; use with caution in controlled hypertension |
| PDE5 inhibitors (sildenafil) | Different mechanisms; additive effects on sexual response | Not studied in combination; use with caution |
| SSRIs | SSRIs commonly cause sexual dysfunction; PT-141 may partially counteract | Active research area; discuss with prescriber |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research suppliers | Varies widely | Quality and purity vary significantly between sources |
| Compounding pharmacies | Prescription required | Higher quality assurance and purity testing |
The bottom line
PT-141 is a hormonal compound with research interest in sexual function, melanocortin, hsdd. While preclinical evidence is encouraging, it has received FDA approval for specific indications. Any use should be under qualified medical supervision.
Best for
- • Researchers studying hormonal signaling and endocrine function
- • Individuals interested in sexual function under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
MT-2
Predecessor peptide (Melanotan II) with broader melanocortin receptor activity
Oxytocin
Downstream mediator of PT-141's sexual arousal effects
Kisspeptin-10
Reproductive hormone peptide studied for sexual arousal via different pathway
MT-1
Related melanocortin peptide with tanning and metabolic effects
Frequently asked questions
References
- [1] Kingsberg SA, Clayton AH, Portman D, et al.. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol (2019). doi: 10.1097/AOG.0000000000003500 PMID: 31599840
- [2] Clayton AH, Althof SE, Kingsberg S, et al.. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (2016). doi: 10.2217/whe-2016-0018 PMID: 27400243
- [3] FDA.. Vyleesi (bremelanotide) Prescribing Information. FDA Label (2019).
- [4] Pfaus JG.. Pathways of sexual desire. J Sex Med (2009). doi: 10.1111/j.1743-6109.2009.01309.x PMID: 19453892
- [5] Molinoff PB, Shadiack AM, Earle D, et al.. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci (2003). doi: 10.1196/annals.1293.021 PMID: 14681152